Evaluation of volatile sedation in the postoperative intensive care of patients recovering from heart valve surgery: protocol for a randomised, controlled, monocentre trial

Armin Niklas Flinspach, Eva Herrmann, Florian Jürgen Raimann, Kai Zacharowski, Elisabeth Hannah Adam, Armin Niklas Flinspach, Eva Herrmann, Florian Jürgen Raimann, Kai Zacharowski, Elisabeth Hannah Adam

Abstract

Introduction: Patients undergoing heart valve surgery are predominantly transferred postoperatively to the intensive care unit (ICU) under continuous sedation. Volatile anaesthetics are an increasingly used treatment alternative to intravenous substances in the ICU. As subject to inhalational uptake and elimination, the resulting pharmacological benefits have been repeatedly demonstrated. Therefore, volatile anaesthetics appear suitable to meet the growing demands of fast-track cardiac surgery. However, their use requires special preparation at the bedside and trained medical and nursing staff, which might limit the pharmacological benefits. The aim of our work is to assess whether the temporal advantages of recovery under volatile sedation outweigh the higher effort of special preparation.

Methods and analysis: The study is designed to evaluate the differences between intravenous sedatives (n=48) and volatile sedatives (n=48) in continued intensive care sedation. This study will be conducted as a prospective, randomised, controlled, single-blinded, monocentre trial at a German university hospital in consenting adult patients undergoing heart valve surgery at a university hospital. This observational study will examine the necessary preparation time, staff consultation and overall feasibility of the chosen sedation method. For this purpose, the continuation of sedation in the ICU with volatile sedatives is considered as one study arm and with intravenous sedatives as the comparison group. Due to rapid elimination and quick awakening after the termination of sedation, closer consultation between the attending physician and the ICU nursing staff is required, in addition to a prolonged setup time. Study analysis will include the required setup time, time from admission to extubation as primary outcome and neurocognitive assessability. In addition, possible operation-specific (blood loss, complications), treatment parameters (catecholamine dosages, lung function) and laboratory results (acute kidney injury, acid base balance (lactataemia), liver failure) as influencing factors will be collected. The study-relevant data will be extracted from the continuous digital records of the patient data management system after the patient has been discharged from the ICU. For statistical evaluation, 95% CIs will be calculated for the median time to extubation and neurocognitive assessability, and the association will be assessed with a Cox regression model. In addition, secondary binary outcome measures will be evaluated using Fisher's exact tests. Further descriptive and exploratory statistical analyses are also planned.

Ethics and dissemination: The study was approved by the Institutional Ethics Board of the University of Frankfurt, Germany (#20-1050). Informed consent of all individual patients will be obtained before randomisation. Results will be disseminated via publication in peer-reviewed journals.

Trial registration number: Clinical trials registration (NCT04958668) was completed on 1 July 2021.

Keywords: adult intensive & critical care; cardiac surgery; health economics; thoracic surgery; valvular heart disease.

Conflict of interest statement

Competing interests: ANF received speaker fees from P.J. Dahlhausen & Co. GmbH, Colone, Germany and received the Sedana Medical Research Grant 2020. The author confirms that the disclosed conflicts of interest of ANF does not alter the adherence to BMJ Open policies on sharing data and materials. EHA received a research grant of the German Research Foundation (AD 592/1-1). The author confirms that the disclosed conflicts of interest of EHA does not alter the adherence to BMJ Open policies on sharing data and materials. KZ has received honoraria for participation in advisory board meetings for Haemonetics and Vifor and received speaker fees from CSL Behring and GE Healthcare. He is the Principal Investigator of the EU-Horizon 2020 project ENVISION (Intelligent plug-and-play digital tool for real-time surveillance of COVID-19 patients and smart decision-making in Intensive Care Units). The author confirms that the disclosed conflicts of interest of KZ does not alter the adherence to BMJ Open policies on sharing data and materials. FJR received speaker fees from Helios Germany, university hospital Würzburg and Keller Medical GmbH. FJR received financial support by HemoSonics LLC, pharma-consult Petersohn and Boehringer Ingelheim. The author confirms that the disclosed conflicts of interest of FJR does not alter the adherence to BMJ Open policies on sharing data and materials.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart of the study design for the evaluation of volatile sedation in postoperative intensive care in patients recovering from heart valve surgery. ICU, intensive care unit.

References

    1. Lee R, Li S, Rankin JS, et al. . Fifteen-year outcome trends for valve surgery in North America. Ann Thorac Surg 2011;91:677–84. 10.1016/j.athoracsur.2010.11.009
    1. London MJ, Shroyer AL, Coll JR, et al. . Early extubation following cardiac surgery in a Veterans population. Anesthesiology 1998;88:1447–58. 10.1097/00000542-199806000-00006
    1. Jerath A, Beattie SW, Chandy T, et al. . Volatile-based short-term sedation in cardiac surgical patients: a prospective randomized controlled trial. Crit Care Med 2015;43:1062–9. 10.1097/CCM.0000000000000938
    1. Liu H, Ji F, Peng K, et al. . Sedation after cardiac surgery: is one drug better than another? Anesth Analg 2017;124:1061–70. 10.1213/ANE.0000000000001588
    1. Jerath A, Ferguson ND, Steel A, et al. . The use of volatile anesthetic agents for long-term critical care sedation (VALTS): study protocol for a pilot randomized controlled trial. Trials 2015;16:560. 10.1186/s13063-015-1083-5
    1. Laferriere-Langlois P, d'''''Aragon F, Manzanares W. Halogenated volatile anesthetics in the intensive care unit: current knowledge on an upcoming practice. Minerva Anestesiol 2017;83:737–48. 10.23736/S0375-9393.17.11735-9
    1. Bellgardt M, Bomberg H, Herzog-Niescery J, et al. . Survival after long-term isoflurane sedation as opposed to intravenous sedation in critically ill surgical patients. Eur J Anaesthesiol 2016;33:6–13. 10.1097/EJA.0000000000000252
    1. Bösel J, Purrucker JC, Nowak F, et al. . Volatile isoflurane sedation in cerebrovascular intensive care patients using AnaConDa(®): effects on cerebral oxygenation, circulation, and pressure. Intensive Care Med 2012;38:1955–64. 10.1007/s00134-012-2708-8
    1. Sackey PV, Martling C-R, Granath F, et al. . Prolonged isoflurane sedation of intensive care unit patients with the anesthetic conserving device. Crit Care Med 2004;32:2241–6. 10.1097/01.CCM.0000145951.76082.77
    1. DAS-Taskforce 2015, Baron R, Binder A, et al. . Evidence and consensus based guideline for the management of delirium, analgesia, and sedation in intensive care medicine. Revision 2015 (DAS-Guideline 2015) - short version. Ger Med Sci 2015;13:Doc19. 10.3205/000223
    1. NICE . AnaConDa-S for sedation with volatile anaesthetics in intensive care. 14. National Institute for Health and Care Excellence, 2020.
    1. Farrell R, Oomen G, Carey P. A technical review of the history, development and performance of the anaesthetic conserving device “AnaConDa” for delivering volatile anaesthetic in intensive and post-operative critical care. J Clin Monit Comput 2018;32:595–604. 10.1007/s10877-017-0097-9
    1. Jerath A, Parotto M, Wasowicz M, et al. . Volatile anesthetics. is a new player emerging in critical care sedation? Am J Respir Crit Care Med 2016;193:1202–12. 10.1164/rccm.201512-2435CP
    1. Bellgardt M, Georgevici AI, Klutzny M, et al. . Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial. Ann Intensive Care 2019;9:118. 10.1186/s13613-019-0594-8
    1. Warltier DC, Myles PS, Daly DJ, et al. . A systematic review of the safety and effectiveness of fast-track cardiac anesthesia. Anesthesiology 2003;99:982–7. 10.1097/00000542-200310000-00035
    1. Cheng DC. Fast track cardiac surgery pathways: early extubation, process of care, and cost containment. Anesthesiology 1998;88:1429–33. 10.1097/00000542-199806000-00002
    1. Ely EW, Truman B, Shintani A, et al. . Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation scale (RASS). JAMA 2003;289:2983–91. 10.1001/jama.289.22.2983

Source: PubMed

3
订阅